title: Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Markova
authors.affiliation: Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
authors.forename: J B
authors.initials: JB
authors.lastname: Schwartz
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Kroetz
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D065128:Endothelin Receptor Antagonists; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D013449:Sulfonamides / Q000009:adverse effects*
chemical_list: D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides; D001189:Aryl Hydrocarbon Hydroxylases